Industry News

Our news page will keep you informed of press releases and news articles on rapid and alternative microbiological method technologies and updates from technology suppliers.

Please click here to submit your news.

mariPOC® Point-of-Care Immunoassay Outperforms Standard Culture in Group A Strep Infection Diagnostics

ArcDia International Ltd has released results from a clinical study comparing its rapid mariPOC® test product to the standard bacterial culture in detection of Group A streptococcal infections. The study results were presented at the GAS Infections 2013 conference, held in Rome in March, by Dr Jukka Vakkila from Mehiläinen. Mehiläinen is a leading private care provider in Finland.

The independent study included 121 patients who were tested for Group A streptococci with bacterial culture and mariPOC® rapid immunoassay. Bacterial culture was positive for 17 (14%) patients, whereas mariPOC® was positive for 31 patients (26%). The relevance of additional positive findings by mariPOC® was confirmed by clinical investigation of the patients. 90% of the additional positive findings were from patients with classical streptococcal tonsillitis symptoms and/or positive test result in a third diagnostic method.

"The results are in line with the previous data suggesting that mariPOC®  is a first rapid test to challenge the sensitivity of bacterial culture", concludes the presentation abstract by Dr Jukka Vakkila, who led the study at Mehiläinen, a leading private care provider in Finland.

"Standard culture was unable to diagnose a significant number of Group A streptococcal infections. In addition, mariPOC® produces results in 20 minutes whereas standard bacterial culture takes two days", comments Janne Koskinen, PhD, R&D Director at ArcDia International Ltd. "The new test enables physicians, for the first time, to trust in negative rapid test findings", he continues.

Earlier in 2013, ArcDia announced new additions to its management team and expansion of its distributor network in Europe.

About mariPOC®

mariPOC®   provides multianalyte diagnostic results for influenza like illnesses and tonsillitis in near patient settings in 20 minutes. The mariPOC® applications are targeted to acute respiratory infections, the most common infectious diseases on Earth. mariPOC® is superior in performance to the conventional test methods, including lateral flow rapid tests and standard bacterial culture. mariPOC® is designed to improve patient management and quality of health care, and it allows timely pathogen-specific diagnostics and medication.

About ArcDia

ArcDia International Ltd is the manufacturer of mariPOC®, world's first multianalyte point-of-care diagnostics test for respiratory tract infections. In the future, the company will develop additional point-of-care tests based on its proprietary ArcDia™ TPX detection technology. (Nature Biotech 2000:18). The technology is available for prominent industrial parties for in-licensing. Currently, ArcDia is actively seeking distribution partners for mariPOC®.

Post a Comment

Previous Post Next Post

Contact Form